Clinical College of Nanjing University School of Medicine, Nanjing, China.
Cancer Biother Radiopharm. 2009 Dec;24(6):717-21. doi: 10.1089/cbr.2009.0652.
Mesenchymal stem cells (MSCs) are a versatile group of nonhematopoietic stem cells with high potency of proliferation and pluripotency of differentiation. Endogenous MSCs circulate in the blood until being called to sites of inflammation or tumors, where they could differentiate into bone, cartilage, fat, or muscle cells to repair or replace damaged tissue. Ectogenous MSCs also demonstrate satisfactory tropism toward primary tumor sites and metastatic foci with low immunogenicity and thus can be exploited as a cell-mediated gene therapy to counteract tumor growth and development. However, tumor-promoting, and even carcinogenetic, effects of MSCs are also observed both in vitro and in vivo, raising potential risks in clinical applications. Recent advances of MSCs in tumor-targeted biotherapy were summarized. New findings of the interaction between MSCs and tumor cells in the tumor microenvironment were expounded.
间充质干细胞（MSCs）是一类具有高增殖潜能和多向分化能力的非造血干细胞。内源性 MSCs 循环于血液中，直到被募集到炎症或肿瘤部位，在那里它们可以分化为骨、软骨、脂肪或肌肉细胞，以修复或替代受损组织。外源性 MSCs 也表现出对原发性肿瘤部位和转移灶的良好趋向性，具有低免疫原性，因此可以作为细胞介导的基因治疗来对抗肿瘤的生长和发展。然而，MSCs 在体外和体内都表现出促进肿瘤甚至致癌的作用，这在临床应用中带来了潜在的风险。本文总结了 MSCs 在肿瘤靶向生物治疗中的最新进展，并阐述了 MSCs 与肿瘤微环境中的肿瘤细胞相互作用的新发现。
